Abstract
Mitochondria are membrane-enclosed organelle found in most eukaryotic cells, where they generate the majority of the cell's supply of adenosine triphosphate (ATP), used as a source of chemical energy. In addition, they are involved in a range of other processes, such as signalling, cellular differentiation, cell death, as well as the control of the cell cycle and cell growth. Mitochondria have been implicated in several neuropsychiatric disorders, in particular, depression, anxiety, schizophrenia, autism, and Alzheimer's dementia. Furthermore, the presence of mutations at the level of mitochondrial or nuclear DNA (mtDNA and nDNA, respectively) has been linked to personality disorders, behavioral disturbances, thought alterations, impulsivity, learning impairment, cognitive failures until dementia. The aim of this paper is to review the literature on the relationship between psychiatric symptoms or syndromes and mtDNA mutations or mitochondrial alterations, while highlighting novel therapeutic targets for a broad range of disorders.
Keywords: Mitochondria, ATP, Genetics, Mitochondrial Diseases, Schizophrenia, Mood Disorders, Anxiety Disorders, Autism, ADHD, Alzheimer's disease
Current Medicinal Chemistry
Title: Mitochondrial Alterations and Neuropsychiatric Disorders
Volume: 18 Issue: 30
Author(s): D. Marazziti, S. Baroni, M. Picchetti, P. Landi, S. Silvestri, E. Vatteroni and M. Catena Dell'Osso
Affiliation:
Keywords: Mitochondria, ATP, Genetics, Mitochondrial Diseases, Schizophrenia, Mood Disorders, Anxiety Disorders, Autism, ADHD, Alzheimer's disease
Abstract: Mitochondria are membrane-enclosed organelle found in most eukaryotic cells, where they generate the majority of the cell's supply of adenosine triphosphate (ATP), used as a source of chemical energy. In addition, they are involved in a range of other processes, such as signalling, cellular differentiation, cell death, as well as the control of the cell cycle and cell growth. Mitochondria have been implicated in several neuropsychiatric disorders, in particular, depression, anxiety, schizophrenia, autism, and Alzheimer's dementia. Furthermore, the presence of mutations at the level of mitochondrial or nuclear DNA (mtDNA and nDNA, respectively) has been linked to personality disorders, behavioral disturbances, thought alterations, impulsivity, learning impairment, cognitive failures until dementia. The aim of this paper is to review the literature on the relationship between psychiatric symptoms or syndromes and mtDNA mutations or mitochondrial alterations, while highlighting novel therapeutic targets for a broad range of disorders.
Export Options
About this article
Cite this article as:
Marazziti D., Baroni S., Picchetti M., Landi P., Silvestri S., Vatteroni E. and Catena Dell'Osso M., Mitochondrial Alterations and Neuropsychiatric Disorders, Current Medicinal Chemistry 2011; 18 (30) . https://dx.doi.org/10.2174/092986711797379221
DOI https://dx.doi.org/10.2174/092986711797379221 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Enhancement of Delayed Audiovisual Response in Parkinson’s Disease: A Comparison with Normal Aged Controls
Neuroscience and Biomedical Engineering (Discontinued) Autoimmunity in Alzheimers Disease as Evidenced by Plasma Immunoreactivity Against RAGE and Aβ42: Complication of Diabetes
Current Alzheimer Research Sculpted Amphiphilic Liposomal Particles for Modifiable Medicinal Applications
Current Drug Discovery Technologies Evidence for the Role of Luteinizing Hormone in Alzheimer Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Galantamine-based Hybrid Molecules with Acetylcholinesterase, Butyrylcholinesterase and γ-Secretase Inhibition Activities
Current Alzheimer Research Role of ARBs in the Blood Hypertension Therapy and Prevention of Cardiovascular Events
Current Drug Targets PCSK9 and LDLR The Yin-Yang in the Cellular Uptake of Cholesterol
Current Hypertension Reviews Anti-VEGF Molecules for the Management of Diabetic Macular Edema
Current Pharmaceutical Design Commentary Research Highlights (Amyloid and Alzheimer's Disease: Easing the Load)
CNS & Neurological Disorders - Drug Targets Antihyperlipidemic and Antiobesity Potential of <i>Aquilaria agallocha</i> and <i>Borago officinalis</i> in Fixed-Dose Combination; A Contingent Probe with Atorvastatin and Orlistat
Current Bioactive Compounds The Role of Anionic Peptide Fragments in 1N4R Human Tau Protein Aggregation
Protein & Peptide Letters Models to Study Atherosclerosis: A Mechanistic Insight
Current Vascular Pharmacology Revisiting the Medical Management of Parkinson’s Disease: Levodopa versus Dopamine Agonist
Current Neuropharmacology Cholinergic Activity and Amyloid Precursor Protein Processing in Aging and Alzheimers Disease
Current Drug Targets - CNS & Neurological Disorders Effects of Transition Metals in the Conversion Mechanism of Prion Protein and in the Pathogenesis of Prion Diseases
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Genotoxicity in Alzheimers Disease: Role of Amyloid
Current Alzheimer Research Host Neuro- Immuno-Endocrine Responses In Periodontal Disease
Current Pharmaceutical Design Hereditary Parkinsonism-Associated Genetic Variations in PARK9 Locus Lead to Functional Impairment of ATPase Type 13A2
Current Protein & Peptide Science CD36 as a Therapeutic Target for Endothelial Dysfunction in Stroke
Current Pharmaceutical Design EPO Relies upon Novel Signaling of Wnt1 that Requires Akt1, FoxO3a,GSK-3β, and β-Catenin to Foster Vascular Integrity during Experimental Diabetes
Current Neurovascular Research